Abramson Cancer Center at Penn Medicine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Abramson Cancer Center at Penn Medicine sits in the top decile of US sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count).

402 total trials 74 currently recruiting 235 completed early-phase tilt top decile by trial count

Abramson Cancer Center at Penn Medicine: 402 sponsored US clinical trials, 74 recruiting.

Abramson Cancer Center at Penn Medicine sponsors 402 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 235 completed. 3 of these trials are in Phase 3-4 (later-stage) and 175 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 20 trials.

Top-decile sponsor footprint

Abramson Cancer Center at Penn Medicine ranks in the top decile of sponsors by registered trial count (#92 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 49/100

235 of 280 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

What is open in the Abramson Cancer Center at Penn Medicine pipeline

74 recruiting of 402 indexed (18% open); 235 completed (58%).

Phase mix: 3 late (III/IV) vs 175 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Abramson Cancer Center at Penn Medicine: open-pipeline peers nationwide

Peers matched on 402 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 10%15%20%25% Total trials Recruiting share Abramson Cancer Center at Penn MedicineCase Comprehensive Cancer CenterUniversity of NebraskaTakedaUniversity of Kansas Medical CenterUniversity of Maryland, BaltimoreHenry Ford Health SystemNew York Institute of TechnologyUniversity of California, San Diego
Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Abramson Cancer Center at Penn Medicine sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 402 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Abramson Cancer Center at Penn Medicine page

402 registered trials is a research-attention snapshot, not an endorsement of Abramson Cancer Center at Penn Medicine or any single study.

  • 74 of Abramson Cancer Center at Penn Medicine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Abramson Cancer Center at Penn Medicine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abramson Cancer Center at Penn Medicine pipeline card: 402 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.